Pioneering In Vivo CAR T Cell Therapies
We are working to improve the treatment experience for patients by developing in vivo CAR T cell therapies designed to be more accessible. At Umoja, our team is harnessing the power of our VivoVec platform to generate chimeric antigen receptor (CAR) T cell therapies in vivo.
Our Science
Our flagship VivoVec platform generates CAR T cells directly in a patient’s body. Our product candidates are designed to enable on-demand administration, removing the multi-week manufacturing step inherent to ex vivo CAR T cell therapies.
In-House Manufacturing
We believe our fully in-house lentiviral manufacturing model is differentiated among in vivo CAR T developers.
In-house manufacturing allows us to reliably and flexibly meet our supply needs, control our manufacturing costs and quality, rapidly translate our science into drug supply, and significantly de-risk our future commercial launch execution.
Our Pipeline
Our pipeline is focused on the treatment of cancers using our in vivo platform, with potential applications in other conditions.
News + Resources
We work at the leading edge of in vivo T cell engineering. Visit our news and resources page to learn more about our scientific journey and the evolution of our company.
Careers
We are focused on advancing the future of CAR T cell therapies. Learn more about our team of experts.